Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Paradigm Biopharmaceuticals ( (AU:PAR) ).
Paradigm Biopharmaceuticals Limited announced the quotation of 8,000,000 ordinary fully paid securities on the ASX, effective July 2, 2025. This move is part of a previously announced transaction, potentially impacting the company’s market presence and providing additional capital for its operations.
The most recent analyst rating on (AU:PAR) stock is a Buy with a A$0.80 price target. To see the full list of analyst forecasts on Paradigm Biopharmaceuticals stock, see the AU:PAR Stock Forecast page.
More about Paradigm Biopharmaceuticals
Paradigm Biopharmaceuticals Limited operates in the biopharmaceutical industry, focusing on the development and commercialization of therapies for inflammatory diseases. The company is listed on the Australian Securities Exchange (ASX) under the code PAR.
Average Trading Volume: 854,010
Technical Sentiment Signal: Sell
Current Market Cap: A$124.6M
Find detailed analytics on PAR stock on TipRanks’ Stock Analysis page.